Business Wire

EUMETSAT

14.12.2022 10:45:38 CET | Business Wire | Press release

Share
Weather Forecasting Set to Enter a New Era With Tonight’s Launch of Next-generation Satellite

Tonight’s launch of a highly advanced meteorological satellite from, Kourou, French Guiana, heralds the start of a new era for weather forecasting in Europe, EUMETSAT Director-General Phil Evans said.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221214005463/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

MTG-I1 is successfully launched on an Ariane-5 rocket from Kourou, French Guiana (Photo: EUMETSAT)

The satellite, MTG-I1, is the first of a new generation of meteorological satellites carrying more advanced and precise instruments for monitoring and forecasting severe weather events such as storms, lightning, fog and wildfires.

It was successfully launched on an Ariane-5 rocket at 21:30 CET and is on its way to its correct orbit, 36,000km above the Equator.

“MTG-I1 will generate images of Europe and Africa every 10 minutes, faster than has been possible up until now, and in higher resolution, more precise detail,” Evans said.

“This data will help meteorologists meet one of their main challenges – timely and accurate forecasts of rapidly developing severe weather events – so that citizens, first responders and civil authorities can take appropriate action.

“The satellite’s lightning imager will continuously map lightning flashes between clouds and from clouds to the ground, which is a first for Europe with significant community and aviation industry safety benefits.”

MTG-I1 – full name Meteosat Third Generation – Imager 1 – will undergo a 12-month commissioning phase, in which its instruments will be calibrated and the data they produce validated, before becoming operational.

It will be operated from EUMETSAT’s headquarters in Darmstadt, Germany.

“Meteosat Third Generation is a European success story,” Evans said. “No European nation could afford to develop and operate such a system on its own. By combining the resources of our 30 member states, including their scientific and technical expertise, we are able to bring about a new era in weather and climate monitoring.”

More information about MTG-I1 can be found here.

Brochure containing facts and figures and other information about the MTG system can be found here.

The full Meteosat Third Generation constellation will comprise two imaging satellites and, for the first time, a sounding satellite. MTG – Sounder 1, is expected to be launched in 2024.

MTG-I1 was built by Thales Alenia Space under contract by the European Space Agency (ESA). ESA is responsible for procuring the satellites from industry fulfilling EUMETSAT’s requirements.

Thales Alenia Space Cannes is the prime industrial partner for the development of the MTG-I satellites. TAS works in close cooperation with:

• OHB-Bremen, which assembled, integrated and tested the platform

• LEONARDO in Italy, which provided the Lightning Imager instrument

• Thales Alenia Space Italy, which delivered the Data Collection and GEO SAR instruments

• Thales Alenia Space Cannes also integrated the Flexible Combined Imager.

For more information, visit the EUMETSAT website.

About EUMETSAT

EUMETSAT, Europe’s meteorological satellite agency, monitors the weather and climate from space. Based in Darmstadt, Germany, EUMETSAT provides its 30 member states with meteorological imagery and data that are essential for keeping their communities safe and for the benefit of critical sectors of their economies.

Three Meteosat Second Generation satellites in geostationary orbit deliver continuous observations of fast developing severe weather events over Europe, Africa and the Indian Ocean. The first of the Meteosat Third Generation satellites was launched in December 2022 and will undergo 12 months’ in-orbit commissioning. Two polar-orbiting Metop satellites provide data of pivotal importance for forecasts up to 10 days ahead. The first of the second-generation Metop satellites is expected to be launched in 2025.

EUMETSAT’s archive of satellite observations over more than 40 years provides climate scientists around the world with long-term, homogenous data necessary for monitoring climate change.

EUMETSAT is a key partner in the European Union’s Copernicus Earth observation programme. It operates the Copernicus Sentinel-3 and -6 ocean-monitoring missions, and will operate the upcoming CO2M mission, to monitor carbon dioxide emissions. EUMETSAT will fly the Copernicus Sentinel-4 and -5 missions on board its own MTG and Metop-SG satellites. Data from these Sentinels, and EUMETSAT’s own missions, are provided to the Copernicus climate, atmosphere monitoring and marine environment services. Along with European Space Agency and the European Centre for Medium-Range Weather Forecasts, EUMETSAT is a partner in the EU’s DestinE initiative, creating digital twins of the entire Earth system.

Together with NASA, NOAA, the EU, ESA and with support from the French Space Agency, CNES, EUMETSAT is a partner in the Jason and Copernicus Sentinel-6 ocean-monitoring missions.

EUMETSAT cooperates with agencies around the world, securing additional satellite data of benefit to weather forecasting and climate monitoring.

EUMETSAT’s 30 member states are: Austria, Belgium, Bulgaria, Croatia, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, the Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, Switzerland, Türkiye and the United Kingdom.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221214005463/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release

For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will

Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release

Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye